 HIV-1
"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
| Descriptor ID |
D015497
|
| MeSH Number(s) |
B04.820.650.589.650.350.400
|
| Concept/Terms |
HIV-1- HIV-1
- Human immunodeficiency virus 1
- HIV-I
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
|
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in this website by year, and whether "HIV-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 9 | 4 | 13 | | 1997 | 4 | 1 | 5 | | 1998 | 13 | 2 | 15 | | 1999 | 10 | 0 | 10 | | 2000 | 13 | 4 | 17 | | 2001 | 7 | 3 | 10 | | 2002 | 11 | 5 | 16 | | 2003 | 8 | 4 | 12 | | 2004 | 12 | 8 | 20 | | 2005 | 12 | 7 | 19 | | 2006 | 18 | 1 | 19 | | 2007 | 13 | 3 | 16 | | 2008 | 14 | 8 | 22 | | 2009 | 10 | 3 | 13 | | 2010 | 18 | 4 | 22 | | 2011 | 23 | 5 | 28 | | 2012 | 18 | 8 | 26 | | 2013 | 16 | 5 | 21 | | 2014 | 27 | 11 | 38 | | 2015 | 16 | 7 | 23 | | 2016 | 22 | 9 | 31 | | 2017 | 14 | 13 | 27 | | 2018 | 17 | 7 | 24 | | 2019 | 14 | 6 | 20 | | 2020 | 12 | 9 | 21 | | 2021 | 12 | 6 | 18 | | 2022 | 19 | 1 | 20 | | 2023 | 13 | 0 | 13 | | 2024 | 11 | 4 | 15 | | 2025 | 16 | 4 | 20 | | 2026 | 6 | 2 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Stabell AC, Lee S, Park DJ, Lavine CL, Espinosa SM, Baharani VA, Patejak R, Nussenzweig MC, Caskey M, Seaman MS, Bieniasz PD, Hatziioannou T. Diverse paths to broadly neutralizing antibody escape among HIV-1 strains. Nat Microbiol. 2026 Jun; 11(6):1573-1584.
-
Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.
-
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.
-
Beck IA, Boyce CL, Bishop MD, Oldroyd AR, du Toit L, Saimen A, Ramarope KM, Hitchcock S, du Plessis NM, Mbogo L, Chohan BH, Maheria P, Oyaro P, Knowles K, Zhang Z, Brummel SS, Drain PK, Smith RA, Gottlieb GS, Abuogi L, Patel RC, Farquhar C, Wiznia A, Ruel TD, Rossouw TM, Hawes SE, Frenkel LM. HIV Resistance to Dolutegravir Varies With Coadministered Agents. Clin Infect Dis. 2026 Apr 30; 82(4):592-596.
-
Meyerson NR, Bauer VL, Fattor WT, Warren CJ, Barbachano-Guerrero A, Weiss MJ, Dirasantha O, Burris BL, Adesina AS, Timpona JL, Feldman ER, Fahy RT, Gendler P, Fainberg A, Nehete PN, Shelton KA, Galvan A, Tustin GW, Koehle PJ, Salinas MD, Davila O, Lindemann EI, Clark SE, Garnett ML, DeMarco CT, Scianna SR, Denny TN, Kuhn JH, Aye PP, Veazey RS, Kezar SM, Wilkerson GK, Sawyer SL. CXCR4-tropic HIV-1 infection in an immunocompetent monkey model. Nat Commun. 2026 Mar 09; 17(1).
-
Mickens KL, Dillon SM, Guo K, Wilson CC, Santiago ML. Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence. Curr HIV/AIDS Rep. 2026 Feb 16; 23(1):5.
-
Mann BT, Sanz M, Chitrakar A, Langlands K, Siegel M, Soriano-Sarabia N. Ex vivo-expanded allogeneic Vd2 T cells specifically reduce reservoirs of HIV-1 following latency reversal. JCI Insight. 2026 Mar 23; 11(6).
-
Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, Yin DE, Moye J, Spiegel H, Gama L, Gaudinski M, Capparelli EV. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. J Antimicrob Chemother. 2026 Jan 19; 81(2).
-
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR. Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. HIV Med. 2026 Mar; 27(3):386-396.
-
Ollerton MT, Folkvord JM, Bush V, Parry DA, Meditz AL, McCarter MD, Yost F, Shikuma CM, Connick E. Lymphoid B cells upregulate HIV-1 ex vivo and are linked to its expression in vivo. PLoS Pathog. 2025 Dec; 21(12):e1013661.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|